From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review)
/in International Publications, IOZK Veröffentlichungen /von 2018-12-10 / Int J Oncol 2019 Feb;54(2):407-419Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?
/in Acute Leukemia, Dendritic Cells, International Publications /von 2018-12-05 / Blood Rev. 2019 03;34:67-83Immunological analysis of phase II glioblastoma dendritic cell vaccine (Audencel) trial: immune system characteristics influence outcome and Audencel up-regulates Th1-related immunovariables
/in Dendritic Cells, Glioblastoma, International Publications /von 2018-12-05 / Acta Neuropathol Commun 2018 12;6(1):135Combination Strategies to Optimize Efficacy of Dendritic Cell-Based Immunotherapy
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications /von 2018-12-05 / Front Immunol 2018;9:2759Autologous Dendritic Cell-Cytokine Induced Killer Cell Immunotherapy Combined with S-1 Plus Cisplatin in Patients with Advanced Gastric Cancer: A Prospective Study
/in Dendritic Cells, Gastric Cancer, International Publications /von 2018-12-04 / Clin. Cancer Res. 2019 Mar;25(5):1494-1504Current State of Dendritic Cell-Based Immunotherapy: Opportunities for Antigen Loading of Different DC Subsets?
/in Dendritic Cells, International Publications /von 2018-12-03 / Front Immunol 2018;9:2804International Journal of Oncology: „Von der Chemotherapie zur biologischen Therapie“, Prof. Dr. Volker Schirrmacher
/in IOZK In der Presse, IOZK Veröffentlichungen /von IOZK
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution